Literature DB >> 16328111

Long-term intrathecal baclofen therapy in ambulatory patients with spasticity.

Saud A Sadiq1, Gary C Wang.   

Abstract

BACKGROUND: Intrathecal baclofen (ITB) is an effective treatment for severe spasticity. In ambulatory patients with spasticity, it is possible that ITB treatment may compromise ambulatory function by unmasking underlying muscle weakness. This retrospective study is designed to determine the long-term ambulatory function in patients receiving ITB.
METHODS: Thirty-six patients with severe spasticity previously screened for response to ITB were implanted with programmable pumps that allowed for continuous infusion of ITB. Patients were followed after implantation from 1 to 13 years.
RESULTS: All 36 patients had decreased spasticity and retained ambulatory function. Three of the 36 patients eventually became paraplegic related to underlying disease progression.
CONCLUSION: ITB therapy may be used in selected ambulatory patients with spasticity and is not associated with loss of ambulatory function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328111     DOI: 10.1007/s00415-005-0060-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.

Authors:  B ASHWORTH
Journal:  Practitioner       Date:  1964-04

2.  Effect on ambulation of continuous intrathecal baclofen infusion.

Authors:  P C Gerszten; A L Albright; M J Barry
Journal:  Pediatr Neurosurg       Date:  1997-07       Impact factor: 1.162

3.  Effect of intrathecal baclofen bolus injection on temporospatial gait characteristics in patients with acquired brain injury.

Authors:  Terry S Horn; Stuart A Yablon; Dobrivoje S Stokic
Journal:  Arch Phys Med Rehabil       Date:  2005-06       Impact factor: 3.966

Review 4.  Pathophysiology of spasticity.

Authors:  P Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-07       Impact factor: 10.154

5.  Intrathecal baclofen for spasticity of spinal origin: seven years of experience.

Authors:  R D Penn
Journal:  J Neurosurg       Date:  1992-08       Impact factor: 5.115

6.  Intrathecal baclofen for treatment of intractable spinal spasticity.

Authors:  N A Abel; R A Smith
Journal:  Arch Phys Med Rehabil       Date:  1994-01       Impact factor: 3.966

7.  Continuous intrathecal baclofen infusion for spasticity of cerebral origin.

Authors:  A L Albright; W B Barron; M P Fasick; P Polinko; J Janosky
Journal:  JAMA       Date:  1993-11-24       Impact factor: 56.272

8.  Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).

Authors:  J C Hobart; A Riazi; D L Lamping; R Fitzpatrick; A J Thompson
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

9.  Intrathecal baclofen therapy for stroke-related spasticity.

Authors:  G E Francisco
Journal:  Top Stroke Rehabil       Date:  2001       Impact factor: 2.119

10.  Intrathecal baclofen for spasticity in cerebral palsy.

Authors:  A L Albright; A Cervi; J Singletary
Journal:  JAMA       Date:  1991-03-20       Impact factor: 56.272

View more
  4 in total

1.  Use of intrathecal clonidine in patients with multiple sclerosis or spastic paraparesis.

Authors:  Joseph K Ho; Saud A Sadiq
Journal:  J Neurol       Date:  2011-11-05       Impact factor: 4.849

2.  [Intrathecal baclofen therapy in ambulatory patients with spastic hemiparesis following stroke. Short report of two cases].

Authors:  S Kästner
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

3.  A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.

Authors:  Francois Bethoux; Ruth Ann Marrie
Journal:  Patient       Date:  2016-12       Impact factor: 3.883

4.  Non-invasive MRI quantification of cerebrospinal fluid dynamics in amyotrophic lateral sclerosis patients.

Authors:  Lucas R Sass; Mohammadreza Khani; Jacob Romm; Marianne Schmid Daners; Kyle McCain; Tavara Freeman; Gregory T Carter; Douglas L Weeks; Brian Petersen; Jason Aldred; Dena Wingett; Bryn A Martin
Journal:  Fluids Barriers CNS       Date:  2020-01-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.